All In Biotech

Drug Trial Radar · NCT06757335

A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

A Multicenter, Open, Dose Escalation/dose Escalation, and Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral HP568 Tablets Alone and in Combination with Palbociclib in Patients with ER+/HER2 Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Jan 7, 2025

Primary completion

Jan 31, 2026

Study completion Nov 27, 2026

Sponsor

Lead sponsor
Hinova Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jan 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or metastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • HP568Drug

    In the I/II stage: HP568 administered QD or BID for 28 day cycles.

  • HP568 in combination with palbociclibDrug

    In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage I: the incidence of TEAE of HP568Time frame: From the first administration dose to 30 calendar days after the last administration dose
  2. Stage I: Incidence of dose limiting toxicity DLT, maximum tolerated dose MTD (if possible).Time frame: 28 days
  3. Stage III: Evaluate safety during the dose escalation phase of combination therapyTime frame: From the first administration dose to 30 calendar days after the last administration dose
  4. Stage III: Evaluate tolerance during the dose escalation phase of combination therapyTime frame: 28 days
  5. Stage III: Evaluate the 24 week clinical benefit rate (CBR) during the dose escalation phase of combination therapyTime frame: Until all patients have completed 24 weeks administration
  6. Stage II: 24 week clinical benefit rate (CBR)Time frame: Until all patients have completed 24 weeks administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.